Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) approved by the FDA to improve wakefulness in adults living with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea
Acquisition accelerates Axsome’s transformation into a global commercial entity ahead of potential near-term launches of AXS-05 in major depressive disorder (MDD) and AXS-07 in migraine
Highly synergistic with Axsome’s existing neuroscience portfolio and Digital Centric Commercialization™ (DCC) platform
Anticipated long-lived exclusivity for Sunosi with potential for significant additional indications
Immediately revenue generating, and expected to be breakeven to operating plan in 2023, and substantially accretive thereafter
Company to host conference call today at 8:00 AM ET
Conference Call Information
Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss the acquisition of Sunosi. To participate in the live conference call, please dial (844) 200-6205 (toll-free domestic) or (929) 526-1599 (international) and use the conference ID 015166. The live webcast can be accessed on the "Webcasts & Presentations" page of the "Investors" section of the Company’s website at axsome.com. A replay of the webcast will be available for approximately 30 days following the live event.
https://finance.yahoo.com/news/axsome-therapeutics-acquire-sunosi-jazz-100000764.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.